Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.380
-0.060 (-4.17%)
At close: Apr 3, 2025, 4:00 PM
1.440
+0.060 (4.35%)
After-hours: Apr 3, 2025, 7:33 PM EDT

Allogene Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Net Income
-257.59-327.27-340.41-182.05-316.38
Upgrade
Depreciation & Amortization
13.6414.214.310.457.44
Upgrade
Asset Writedown & Restructuring Costs
15.7213.25--0.15
Upgrade
Loss (Gain) From Sale of Investments
-6.390.192.896.963.25
Upgrade
Loss (Gain) on Equity Investments
1.6910.6712.884.0967.31
Upgrade
Stock-Based Compensation
51.7465.9583.680.8265.26
Upgrade
Other Operating Activities
5.696.582.33-73.133.96
Upgrade
Change in Accounts Payable
-0.5-7.54.87-0.770.62
Upgrade
Change in Unearned Revenue
---0.02-38.338.35
Upgrade
Change in Other Net Operating Assets
-24.3-13.81-0.957.1214.96
Upgrade
Operating Cash Flow
-200.3-237.73-220.52-184.81-115.09
Upgrade
Capital Expenditures
-0.69-1.52-5.19-21.45-65.96
Upgrade
Investment in Securities
76.38164.81111.35185.1-439.17
Upgrade
Investing Cash Flow
75.69163.29106.16163.66-505.12
Upgrade
Issuance of Common Stock
114.495.72.9511.96633.59
Upgrade
Other Financing Activities
2.28----
Upgrade
Financing Cash Flow
116.6895.72.9511.96633.59
Upgrade
Net Cash Flow
-7.9421.25-111.41-9.1913.38
Upgrade
Free Cash Flow
-200.99-239.25-225.71-206.26-181.05
Upgrade
Free Cash Flow Margin
-913609.09%-251841.05%-144685.90%-180.79%-
Upgrade
Free Cash Flow Per Share
-1.03-1.52-1.58-1.52-1.50
Upgrade
Levered Free Cash Flow
-99.13-134.26-111.74-85.97-97.89
Upgrade
Unlevered Free Cash Flow
-99.02-134.26-111.74-85.97-97.89
Upgrade
Change in Net Working Capital
2.7816.34-5.2743.17-56.77
Upgrade
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q